{"id":46230,"date":"2022-07-15T14:02:13","date_gmt":"2022-07-15T12:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/"},"modified":"2022-07-15T14:02:13","modified_gmt":"2022-07-15T12:02:13","slug":"scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/","title":{"rendered":"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the company will present new data that highlight the development of its highly selective, context-dependent TGF\u03b21 antibody that inhibits proTGF\u03b21 activation selectively in the context of its extracellular matrix presenting partner, latent TGF\u03b2 binding protein (\u201cLTBP\u201d; the target is collectively identified as \u201cLTBP-TGF\u03b21\u201d). The data show reduction of TGF\u03b21 signaling and reduction of fibrosis in relevant preclinical models in vivo<\/i>. These findings will be presented in an oral and poster presentation at the 2022 FASEB Science Research Conference (SRC), taking place between July 17\u201321, 2022 in Malahide, Ireland.\n<\/p>\n

<\/a><\/p>\n

\n\u201cTGF\u03b21 plays a complex role in human disease, including fibrosis progression and immune regulation. Our earlier work established the isoform-selective approach to TGFb1 inhibition,\u201d said Gregory Carven, Ph.D., Chief Scientific Officer of Scholar Rock. \u201cThis new research extends this idea further, showing that highly selective antibodies that inhibit TGF\u03b21 associated with specific extracellular matrix proteins can distinguish between the profibrotic and immunomodulatory activities of TGF\u03b21, and could potentially provide a safe and effective way to treat a wide range of fibrotic diseases\u2014such as Alport syndrome, scleroderma or idiopathic pulmonary fibrosis\u2014with a lower potential for immune-mediated side-effects.\u201d\n<\/p>\n

\nData being featured at FASEB SRC will be made available in the Publications & Posters section of Scholar Rock\u2019s website after the presentation:\n<\/p>\n

\nOral Presentation<\/b>: Selective Targeting of Matrix-Associated TGFBeta1 as an Attractive Approach for Anti-Fibrotic Therapy
\n
Presenter<\/b>: Rohan Manohar, Ph.D., Associate Director of Discovery Biology at Scholar Rock
\n
Session: <\/b>TGF-\u03b2 Superfamily: Signaling in Development and Disease
\n
Time<\/b>: July 21, 9:45 a.m. CET\n<\/p>\n

\nFor conference information visit https:\/\/www.faseb.org\/meetings-and-events\/src-events\/the-tgf-%CE%B2-superfamily-conference-signaling-in-development-and-disease<\/a>.\n<\/p>\n

\nAbout Scholar Rock
\n
<\/b>Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock\u2019s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com<\/a> or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https:\/\/www.linkedin.com\/company\/scholar-rock\/<\/a>). Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com<\/a>, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.\n<\/p>\n

\nScholar Rock\u00ae is a registered trademark of Scholar Rock, Inc.\n<\/p>\n

\nForward-Looking Statements
\n
<\/b>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock\u2019s future expectations, plans and prospects, including without limitation, Scholar Rock\u2019s expectations regarding its growth, strategy, and progress and indication selection and development timing, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as \u201cmay,\u201d \u201cmight,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cfuture,\u201d \u201cpotential,\u201d or \u201ccontinue,\u201d and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, Scholar Rock\u2019s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock\u2019s nonclinical and preclinical studies and clinical trials, and Scholar Rock\u2019s ability to manage expenses and to obtain additional funding when needed to support its business activities, as well as those risks more fully discussed in the section entitled “Risk Factors” in Scholar Rock\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock\u2019s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock\u2019s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nScholar Rock:<\/b>
Investors
\n
Rushmie Nofsinger
\n
Scholar Rock
\n
rnofsinger@scholarrock.com<\/a>
ir@scholarrock.com<\/a>
857-259-5573\n<\/p>\n

\nMedia<\/b>
Ariane Lovell
\n
Finn Partners
\n
ariane.lovell@finnpartners.com<\/a>
media@scholarrock.com<\/a>
917-565-2204\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the company will present new data that highlight the development of its highly selective, context-dependent TGF\u03b21 antibody that inhibits proTGF\u03b21 activation selectively in the context … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46230","6":"format-standard","7":"category-industry"},"yoast_head":"\nScholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf\u03b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the company will present new data that highlight the development of its highly selective, context-dependent TGF\u03b21 antibody that inhibits proTGF\u03b21 activation selectively in the context ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf\u03b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-15T12:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220715005082\/en\/1514694\/21\/ScholarRock_Logo_TM_Full_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference\",\"datePublished\":\"2022-07-15T12:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/\"},\"wordCount\":988,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005082\\\/en\\\/1514694\\\/21\\\/ScholarRock_Logo_TM_Full_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/\",\"name\":\"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005082\\\/en\\\/1514694\\\/21\\\/ScholarRock_Logo_TM_Full_Color.jpg\",\"datePublished\":\"2022-07-15T12:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005082\\\/en\\\/1514694\\\/21\\\/ScholarRock_Logo_TM_Full_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005082\\\/en\\\/1514694\\\/21\\\/ScholarRock_Logo_TM_Full_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf\u03b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/","og_locale":"en_US","og_type":"article","og_title":"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the company will present new data that highlight the development of its highly selective, context-dependent TGF\u03b21 antibody that inhibits proTGF\u03b21 activation selectively in the context ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf\u03b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-15T12:02:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220715005082\/en\/1514694\/21\/ScholarRock_Logo_TM_Full_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference","datePublished":"2022-07-15T12:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/"},"wordCount":988,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005082\/en\/1514694\/21\/ScholarRock_Logo_TM_Full_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/","url":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/","name":"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005082\/en\/1514694\/21\/ScholarRock_Logo_TM_Full_Color.jpg","datePublished":"2022-07-15T12:02:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220715005082\/en\/1514694\/21\/ScholarRock_Logo_TM_Full_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220715005082\/en\/1514694\/21\/ScholarRock_Logo_TM_Full_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/scholar-rock-to-present-new-preclinical-data-on-its-targeted-approach-to-the-ltbp-tgf%ce%b21-complex-for-anti-fibrotic-therapy-at-the-2022-faseb-science-research-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46230"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46230\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}